The Relative Strength (RS) Rating for Vaxcyte moved into a new percentile Tuesday, as it got a lift from 69 to 73.
IBD's proprietary RS Rating measures market leadership by using a 1 (worst) to 99 (best) score that identifies how a stock's price performance over the trailing 52 weeks compares to the rest of the market.
Decades of market research shows that the best stocks typically have an RS Rating north of 80 in the early stages of their moves. See if Vaxcyte can continue to rebound and clear that threshold.
How To Invest In Stocks In Both Bull And Bear Markets
Vaxcyte is now considered extended and out of buy range after clearing a 76.00 buy point in a second-stage cup with handle. See if the stock forms a new pattern or follow-on buying opportunity like a three-weeks tight or pullback to the 50-day or 10-week moving average.
The company posted 0% earnings growth in the latest quarterly report. Sales increased 0%.
Vaxcyte holds the No. 244 rank among its peers in the Medical-Biomed/Biotech industry group. Catalyst Pharmaceuticals, ADMA Biologics and Exelixis are among the top 5 highly rated stocks within the group.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
